Skip to main content

Humacyte, Inc. (HUMA)

NASDAQ: HUMA · IEX Real-Time Price · USD
13.82 -0.03 (-0.22%)
Sep 22, 2021 12:34 PM EDT - Market open
Market Cap1.42B
Revenue (ttm)1.39M
Net Income (ttm)-69.15M
Shares Out103.00M
EPS (ttm)-3.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume102,016
Open14.50
Previous Close13.85
Day's Range13.82 - 14.50
52-Week Range9.93 - 17.45
Betan/a
Analystsn/a
Price Target19.00 (+37.5%)
Est. Earnings Daten/a

About HUMA

Humacyte, Inc., a clinical-stage biotechnology platform company, develops and manufactures off-the-shelf bioengineered human tissues. The company develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions for complex organ disease. Its Human Acellular Vessel (HAV), a regenerative vascular conduit that is in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company was founded...

IndustryBiotechnology
Founded2004
Stock ExchangeNASDAQ
Ticker SymbolHUMA
Full Company Profile

Financial Performance

In 2020, Humacyte's revenue was $1.49 million, a decrease of -75.90% compared to the previous year's $6.19 million. Losses were -$66.52 million, -22.12% less than in 2019.

Financial Statements

News

Humacyte Announces Issuance of Three Additional U.S. Patents Covering its Proprietary Universally Implantable Bioengi...

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercia...

2 days ago - GlobeNewsWire

Humacyte Leadership to Present at Five Scientific Events in September

DURHAM, N.C., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercia...

5 days ago - GlobeNewsWire

3 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Other symbols:FEYEVAL
3 weeks ago - Benzinga

Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today a...

3 weeks ago - GlobeNewsWire

Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business...

NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that it has filed a defini...

1 month ago - GlobeNewsWire

EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack'

Humacyte is set to go public via the special purpose acquisition company Alpha Healthcare Acquisition Corp (NASDAQ: AHAC) in a deal that values the company at around $800 million.  Humacyte founder and ...

3 months ago - Benzinga

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Alpha Healthcare Acquisition Corp. - AHAC

NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...

5 months ago - PRNewsWire

2 SPAC Stocks That Could Be 10-Baggers

They could even deliver greater gains than just a 10-times return.

6 months ago - The Motley Fool

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today ...

6 months ago - GlobeNewsWire

Should You Invest in Humacyte Before the SPAC Merger?

The biotech is going public through the special acquisition company (SPAC).

6 months ago - The Motley Fool

Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International S...

DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today ...

6 months ago - GlobeNewsWire

Why Humacyte Is Going Public Via SPAC

Feb.17 -- Dr. Laura Niklason, chief executive officer and founder of Humacyte, discusses the biotech company's decision to go public through a merger with Alpha Healthcare Acquisition Corp., a special p...

7 months ago - Bloomberg Technology

Regenerative Tissue Developer Humacyte Going Public Via SPAC

Humacyte is a leader in regenerative medicine, growing human tissue in the lab that can be transplanted into any patient.

7 months ago - The Motley Fool

Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioenginee...

NEW YORK and DURHAM, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced ex...

7 months ago - GlobeNewsWire

Alpha Healthcare Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencin...

NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (the “Company”) announced today that holders of the units sold in the Company's initial public offering of 10,000,000 units...

10 months ago - GlobeNewsWire

Alpha Healthcare Acquisition Corp. Announces Closing of $100,000,000 Initial Public Offering

New York, NY, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ: AHACU) (the “Company”) announced today that it closed its initial public offering of 10,000,000 units at a ...

11 months ago - GlobeNewsWire

Alpha Healthcare Acquisition Corp. Announces Pricing of $100,000,000 Initial Public Offering

New York, NY, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 10,000,000 units at $10.00 per unit. T...

1 year ago - GlobeNewsWire